NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02738346,SCLC on the 2nd Line With Relapsed After Response to Chemotherapy GFPC 01-2013,https://clinicaltrials.gov/study/NCT02738346,CBPC,UNKNOWN,The purpose of this study was to determine prospectively in all patients with SCLC in second line therapy that progression-free survival with the expected reintroduction of platinum / etoposide is greater progression-free survival in the standard arm (topotecan ) in patients who have relapsed at least three months after initial chemotherapy with platinum-etoposide,NO,Small Cell Lung Cancer,DRUG: Carboplatin|DRUG: Etoposide|DRUG: Topotecan|DEVICE: CT scans,"Benefit in terms of progression-free survival of a therapeutic strategy, Determine the benefit in terms of progression-free survival of a therapeutic strategy by second-line carboplatin etoposide versus topotecan in patients who relapsed at least three months after the initial chemotherapy with platinum-etoposide., 18 weeks","Objective response rate assessed by RECIST, 18 weeks|Overall survival, 18 weeks|Name and number of with treatment-related adverse events as assessed by CTCAE v4.0""., 18 weeks|The quality of life, the method of assessment : questionnaire, 18 weeks",,"University Hospital, Angers",,ALL,"ADULT, OLDER_ADULT",PHASE3,164,OTHER_GOV,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,CHU-P 2012-08|GFPC 01-2013,2013-07,2017-07,2017-07,2016-04-14,,2016-04-25,"Angers University Hospital, Angers, 49933, France",
